This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Link between effectiveness and cost data
The costing was carried out on the same sample of patients as that used in the effectiveness study. It was unclear whether or not the costing was conducted prospectively or retrospectively.
Study sample
No power calculations to determine the sample size were reported. All of the patients who met the inclusion criteria during the time period were included in the pool of PD patients who might get peritonitis and then be part of the study. Twenty-two episodes of peritonitis were treated with vancomycin and 20 were treated with cefazolin.
Study design
This was a single-centre, randomised controlled trial in which each episode of illness counted as a new case and would be randomised to one of the two treatments (vancomycin or cefazolin). Each episode was assessed for 4 to 5 weeks.
Analysis of effectiveness
The basis of the analysis was intention to treat. The health outcomes were the WBC count, the number of relapses, evidence of exit site infection, tunnel infection, evidence of Enterococcus and a measure of abdominal pain. The number of patients whose catheters were removed was recorded, along with the reasons for the removal.
Effectiveness results
The WBC count (per mL) of patients treated with vancomycin fell from 1,431 (+/-432) to 8.2 (+/-3.2) at the end of treatment, whilst that of patients treated with cefazolin fell from 1,915 (+/-676) to 7.6 (+/-2.8). There was no statistically significant difference between the two groups.
There were 3 relapses in 2 patients in the vancomycin group (all S. aureus) and 2 relapses in the cefazolin group (both S. epidermis). There was no statistically significant difference between the two groups. All relapses were successfully treated with vancomycin.
Two patients in the cefazolin group had evidence of exit-site infection. There were no cases of tunnel infection. There were 2 cases of Enterococcus in the cefazolin group that responded to treatment with vancomycin.
The mean abdominal pain score fell from an average of 3.5 to less than 1 for vancomycin, and from 2.7 to less than 1 for cefazolin. There was no statistically significant difference between the two groups.
There were no cases of vancomycin-resistant organisms isolated during the study.
Catheters were removed from 8 patients in the vancomycin group. The reasons given included gram-negative infection (2 patients), fungi (1), recurrent peritonitis with gram-positive organisms (3), failure to thrive (1), and poor compliance (1).
Catheters were removed from 4 patients in the cefazolin group. The reasons given were gram-negative peritonitis (2 patients), fungal peritonitis (1), and recurrent gram-positive infection that would not respond to vancomycin (1). The pvalue for the difference in catheter removal rate was 0.63.
Validity of estimate of measure of effectiveness
The effectiveness data were obtained from a randomised controlled trial in which peritonitis episodes, rather than patients, were randomised to receive one of the two antibiotics. There was no sample selection since all of the patients who met the inclusion criteria were included in the study. The authors were aware that the patients preferred vancomycin, but they did not include any measure of patient satisfaction that could have registered this preference.
Validity of estimate of measure of benefit
No summary measure of health benefit was calculated.
Validity of estimate of costs
The costs were broken down into components for a peritonitis episode, and for most of these components the quantities were given so that the price could be deduced. No indirect costs were given. This omission might have prevented the authors' conclusions from being more robust, as vancomycin appeared to have lower indirect costs than cefazolin. The quantities and prices were both taken from a single study. No statistical or sensitivity analyses of the prices or quantities were carried out. No price year was reported.
